Abbott reports fourth-quarter sales that miss analysts’ estimates.

Abbott’s stock has fallen by over 7% despite reporting strong fiscal year 2025 (FY25) revenues of $44.32bn, representing a ...

The Medical Devices business remained a standout performer at Abbott, with Q4 sales up 12.3% to $5.68 billion. Abbott ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Pricing challenges in Abbott’s nutrition business and lower than expected sales of continuous glucose monitors drove down the ...

Abbott Laboratories forecast a 1Q profit that was lower than Wall Street expected and missed 4Q sales estimates after its ...

Some of medtech's most innovative technologies were on display at the Consumer Electronics Show (CES) in Las Vegas this week.

Abbott is teaming up with AtaCor Medical to develop a next-generation implantable cardioverter defibrillator (ICD) designed ...

AtaCor, a cardiac rhythm management (CRM) company, develops extravascular defibrillation technologies. Its offerings aim to ...

Abbott Park, Ill.-based Abbott Laboratories and Saint Paul, Minn.-based St. Jude Medical — which Abbott is in the process of acquiring for $25 billion — plan to sell several medical devices to ...

Abbott Laboratories will divest its eye care division to Johnson & Johnson for about $4.33 billion in cash, reported Reuters. Here are five things to know about the deal. Abbott, which recently ...